Somatostatin modulators and uses thereof

• US 10,597,377 B2
• Filed: 05/08/2019
• Issued: 03/24/2020
• Est. Priority Date: 07/14/2016
• Status: Active Grant

• Current Assignee: Crinetics Pharmaceuticals, Inc.
• Original Assignee: Crinetics Pharmaceuticals, Inc.
• Inventors: Zhao, Jian, Wang, Shimiao, Zhu, Yunfei
• Primary Examiner(s): Seaman, D Margaret M
• Application Number:
  US16/407,031
• Publication Number:
  US 20190382367A1
• Time in Patent Office: 321 Days
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/08 for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
• CPC Class Codes: C07D 401/04 directly linked by a ring-member-to-ring-member bond
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 405/14 containing three or more hetero rings
• CPC Class Codes: C07D 413/14 containing three or more hetero rings
• CPC Class Codes: C07D 471/04 Ortho-condensed systems
• CPC Class Codes: C07D 498/04 Ortho-condensed systems

Abstract

Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

Claims

1. A compound that has the following structure:

2. A compound that has the following structure:

3. A pharmaceutically acceptable salt of a compound that has the following structure:

4. A pharmaceutical composition comprising a compound that has the following structure:

5. The pharmaceutical composition of claim 4, comprising a pharmaceutically acceptable salt of the compound that has the following structure:

6. A method of treating acromegaly, a neuroendocrine tumor, or a combination thereof in a human comprising administering to the human in need thereof a compound that has the following structure:

7. The method of claim 6, comprising administering to the human in need thereof a pharmaceutically acceptable salt of the compound that has the following structure:

8. A method of treating acromegaly in a human comprising administering to the human in need thereof a compound that has the following structure:

9. The method of claim 8, comprising administering to the human in need thereof a pharmaceutically acceptable salt of the compound that has the following structure: